Choice Defines QALYs A US Valuation of the EQ-5D-5L

被引:41
|
作者
Craig, Benjamin M. [1 ]
Rand, Kim [2 ,3 ]
机构
[1] Univ S Florida, Dept Econ, 4202 E Fowler Ave,CMC206A, Tampa, FL 33620 USA
[2] Univ Oslo, Dept Hlth Management & Hlth Econ, Oslo, Norway
[3] Akershus Univ Hosp, Hlth Serv Res Ctr, Lorenskog, Norway
基金
美国国家卫生研究院;
关键词
quality-adjusted life years; patient preference; choice behavior; health valuation; cost-utility analyses; value of life; quality of life; patient reported outcome measures; TIME TRADE-OFF; SUBJECTIVE HEALTH OUTCOMES; UNITED-STATES; VALUE SET; PREFERENCE RESEARCH; VALUES; TTO; DURATION; ADULTS; MODEL;
D O I
10.1097/MLR.0000000000000912
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: The 5-level version of the EQ-5D (EQ-5D-5L) was introduced as an improvement on the original 3-level version (EQ-5D-3L). To date, 6 country-specific value sets have been published for EQ-5D-5L and 9 US value sets have been published for other instruments. Our aims were to (1) produce EQ-5D-5L values on a quality-adjusted life year (QALY) scale from the perspective of US adults and (2) compare them with US EQ-5D-3L values and the other country-specific EQ-5D-5L values. Methods: In 2016, 8222 US respondents from all 50 states and Washington, DC completed an online survey including a discrete choice experiment with 20 paired comparisons. Each comparison asked respondents, "Which do you prefer?" regarding a pair of alternatives described using EQ-5D-5L and lifespan attributes. On the basis of more than 50 choices on each of the 3160 pairs, we estimated EQ-5D-5L values on a QALY scale and compared them with the US EQ-5D-3L values and the other country-specific EQ-5D-5L values. Results: Ranging from -0.287 (55555) to 0.992 (11121) on a QALY scale, the estimated EQ-5D-5L values were similar to the US EQ-5D-3L values. Compared with the US EQ-5D-3L values, the values exhibited greater sensitivity and specificity and higher correlation with the EQ-5D-5L values of other countries, particularly England. Conclusions: Like previous US valuation studies, this study produced nationally representative EQ-5D-5L values on a QALY scale. The results further demonstrate the advantages of the EQ-5D-5L over its 3-level predecessor as a preference-based summary measure of health-related quality of life from the perspective of US adults.
引用
收藏
页码:529 / 536
页数:8
相关论文
共 50 条
  • [1] CHOICE DEFINES QALYS: A US VALUATION OF THE EQ-5D-5L
    Craig, B. M.
    Rand, K.
    VALUE IN HEALTH, 2018, 21 : S12 - S12
  • [2] Valuation of the EQ-5D-5L in Taiwan
    Lin, Hsiang-Wen
    Li, Chia-Ing
    Lin, Fang-Ju
    Chang, Jen-Yu
    Gau, Churn-Shiouh
    Luo, Nan
    Pickard, A. Simon
    Goni, Juan M. Ramos
    Tang, Chao-Hsiun
    Hsu, Chien-Ning
    PLOS ONE, 2018, 13 (12):
  • [3] QALYs for COVID-19: A Comparison of US EQ-5D-5L Value Sets
    Stephen Poteet
    Benjamin M. Craig
    The Patient - Patient-Centered Outcomes Research, 2021, 14 : 339 - 345
  • [4] EQ-5D-5L valuation study for Portugal
    Ferreira, Pedro L.
    Antunes, Patricia
    Ferreira, Lara N.
    Pereira, Luis N.
    QUALITY OF LIFE RESEARCH, 2017, 26 (01) : 87 - 87
  • [5] QALYs for COVID-19: A Comparison of US EQ-5D-5L Value Sets
    Poteet, Stephen
    Craig, Benjamin M.
    PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 2021, 14 (03): : 339 - 345
  • [6] The EQ-5D-5L valuation study in Korea
    Seon-Ha Kim
    Jeonghoon Ahn
    Minsu Ock
    Sangjin Shin
    Jooyeon Park
    Nan Luo
    Min-Woo Jo
    Quality of Life Research, 2016, 25 : 1845 - 1852
  • [7] EQ-5D-5L Valuation for the Malaysian Population
    Shafie, Asrul Akmal
    Thakumar, Annushiah Vasan
    Lim, Ching Jou
    Luo, Nan
    Rand-Hendriksen, Kim
    Yusof, Faridah Aryani Md
    PHARMACOECONOMICS, 2019, 37 (05) : 715 - 725
  • [8] EQ-5D-5L VALUATION STUDY IN TAIWAN
    Lin, H.
    Li, C.
    Lin, F.
    Chang, J.
    Gau, C.
    Luo, N.
    Pickard, A. S.
    Goni, Ramos J. M.
    Tang, C.
    Hsu, C.
    VALUE IN HEALTH, 2018, 21 : S91 - S91
  • [9] EQ-5D-5L Valuation for the Malaysian Population
    Asrul Akmal Shafie
    Annushiah Vasan Thakumar
    Ching Jou Lim
    Nan Luo
    Kim Rand-Hendriksen
    Faridah Aryani Md Yusof
    PharmacoEconomics, 2019, 37 : 715 - 725
  • [10] The EQ-5D-5L Valuation study in Thailand
    Pattanaphesaj, Juntana
    Thavorncharoensap, Montarat
    Ramos-Goni, Juan Manuel
    Tongsiri, Sirinart
    Ingsrisawang, Lily
    Teerawattananon, Yot
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (05) : 551 - 558